{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:04:41Z","timestamp":1758279881192,"version":"3.40.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11883-020-00856-6","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T09:02:36Z","timestamp":1592470956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7949-6173","authenticated-orcid":false,"given":"Xiaoming","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Al Rifai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anandita","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"issue":"12","key":"856_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11883-019-0813-7","volume":"21","author":"X Jia","year":"2019","unstructured":"Jia X, Al Rifai M, Gluckman TJ, Birnbaum Y, Virani SS. Highlights from selected cardiovascular disease prevention studies presented at the 2019 European Society of Cardiology Congress. Curr Atheroscler Rep. 2019;21(12):46.","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"856_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11883-019-0789-3","volume":"21","author":"M Al Rifai","year":"2019","unstructured":"Al Rifai M, Jia X, Al-Mallah MH, Miedema MD, Martin SS, Virani SS. Major randomized clinical trials in cardiovascular disease prevention presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2019;21(8):31.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"856_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-020-0822-6","volume":"22","author":"A Mehta","year":"2020","unstructured":"Mehta A, Mahtta D, Gulati M, Sperling LS, Blumenthal RS, Virani SS. Cardiovascular disease prevention in focus: highlights from the 2019 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2020;22(1):3.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"856_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/ncpcardio0836","volume":"4","author":"AK Soutar","year":"2007","unstructured":"Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214\u201325.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"4","key":"856_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11883-015-0491-z","volume":"17","author":"A Brautbar","year":"2015","unstructured":"Brautbar A, Leary E, Rasmussen K, Wilson DP, Steiner RD, Virani S. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep. 2015;17(4):491.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"856_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s11883-013-0382-0","volume":"16","author":"SJ Bandeali","year":"2014","unstructured":"Bandeali SJ, Daye J, Virani SS. Novel therapies for treating familial hypercholesterolemia. Curr Atheroscler Rep. 2014;16(1):382.","journal-title":"Curr Atheroscler Rep"},{"issue":"32","key":"856_CR7","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"15","key":"856_CR8","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","volume":"75","author":"MK Ito","year":"2015","unstructured":"Ito MK, Watts GF. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs. 2015;75(15):1715\u201324.","journal-title":"Drugs."},{"issue":"22","key":"856_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"\u2022\u2022 Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107 Large, randomized, placebo-controlled trial assessing the efficacy and safety of alirocumab in risk reduction of ASCVD outcomes.","journal-title":"N Engl J Med"},{"key":"856_CR10","unstructured":"Blom D, editor Alirocumab efficacy and safety in adults with homozygous familial hypercholesterolemia (ODYSSEY HoFH). American College of Cardiology 2020 Scientific Session; March 30, 2020."},{"issue":"3","key":"856_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"856_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","volume":"4","author":"X Wang","year":"2019","unstructured":"Wang X, Musunuru K. Angiopoietin-like 3: from discovery to therapeutic gene editing. JACC Basic Transl Sci. 2019;4(6):755\u201362.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"856_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296\u20137.","journal-title":"N Engl J Med"},{"key":"856_CR14","unstructured":"Raal F, editor Evinacumab in Patients with Homozygous Familial Hypercholesterolemia. American College of Cardiology 2020 Scientific Session; March 30, 2020."},{"issue":"4","key":"856_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"\u2022 Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5(4):280\u201390 Evaluation of the efficacy and safety of evolocumab in the reduction of LDL-C in a subset of patients with HoFH enrolled in the open-labeled, non-randomized phase III trial.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"856_CR16","unstructured":"Eisenberg M, editor A randomized controlled trial evaluating the efficacy and safety of e-cigarettes for smoking cessation. American College of Cardiology 2020 Scientific Session; March 30, 2020."},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444\u201351.","journal-title":"Lancet."},{"key":"856_CR18","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020.","DOI":"10.1056\/NEJMoa1915928"},{"key":"856_CR19","doi-asserted-by":"crossref","unstructured":"\u2022 Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020; Two phase III trials on the efficacy and safety of inclisiran in the reduction of LDL-C in patients with ASCVD or ASCVD risk equivalent.","DOI":"10.1056\/NEJMoa1912387"},{"key":"856_CR20","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020. Phase III trial on the efficacy and safety of inclisiran in the reduction of LDL-C in patients with heterozygous familial hypercholesterolemia."},{"key":"856_CR21","unstructured":"Wright RS, editor ORION: A pooled analysis of phase III studies of inclisiran. American College of Cardiology 2020 Scientific Session; March 30, 2020."},{"issue":"1","key":"856_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"\u2022\u2022 Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380(1):11\u201322 Large, randomized, placebo-controlled cardiovascular outcome trial of icosapent ethyl assessing efficacy and safety in the reduction of ASCVD risk.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"856_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-019-0763-0","volume":"21","author":"X Jia","year":"2019","unstructured":"Jia X, Kohli P, Virani SS. Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials. Curr Atheroscler Rep. 2019;21(1):1.","journal-title":"Curr Atheroscler Rep"},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/VHRM.S210149","volume":"16","author":"X Jia","year":"2020","unstructured":"Jia X, Koh S, Al Rifai M, Blumenthal RS, Virani SS. Spotlight on icosapent ethyl for cardiovascular risk reduction: evidence to date. Vasc Health Risk Manag. 2020;16:1\u201310.","journal-title":"Vasc Health Risk Manag"},{"key":"856_CR25","unstructured":"Bhatt DL, editor EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl-intervention trial. American College of Cardiology 2020 Scientific Session; March 30, 2020."},{"issue":"18","key":"856_CR26","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1001\/jama.2019.3893","volume":"321","author":"LP Sugrue","year":"2019","unstructured":"Sugrue LP, Desikan RS. What are polygenic scores and why are they important? JAMA. 2019;321(18):1820\u20131.","journal-title":"JAMA."},{"key":"856_CR27","unstructured":"Ference BA, editor Integrating the effect of polygenic scores, low density lipoproteins and systolic blood pressure on the lifetime risk of cardiovascular disease. American College of Cardiology 2020 Scientific Session; March 28, 2020."},{"issue":"7","key":"856_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jama.2019.21782","volume":"323","author":"JD Mosley","year":"2020","unstructured":"Mosley JD, Gupta DK, Tan J, Yao J, Wells QS, Shaffer CM, et al. Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. JAMA. 2020;323(7):627\u201335.","journal-title":"JAMA."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00856-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:28:01Z","timestamp":1744176481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00856-6","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"type":"print","value":"1523-3804"},{"type":"electronic","value":"1534-6242"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"18 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Virani reports grants from Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family, other from American College of Cardiology, other from Steering Committee Member, outside the submitted work.Dr. Jia has nothing to disclose.Dr. Al Rifai has nothing to disclose.Dr. Liu has nothing to disclose.Dr. Agrawala has nothing to disclose.Dr. Gulati has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/Animal Rights Statement"}}],"article-number":"32"}}